- Home
- ECAT vs SNDX Comparison
ECAT vs SNDX Comparison
Compare ECAT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECAT | SNDX |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ECAT | SNDX |
|---|---|---|
| Price | $15.80 | $20.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $36.92 |
| AVG Volume (30 Days) | 278.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | ★ $111,304,000.00 |
| Revenue This Year | N/A | $620.14 |
| Revenue Next Year | N/A | $115.42 |
| P/E Ratio | $7.15 | ★ N/A |
| Revenue Growth | N/A | ★ 595.65 |
| 52 Week Low | $14.02 | $8.58 |
| 52 Week High | $17.30 | $21.22 |
Technical Indicators
Market Signals| Indicator | ECAT | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 67.42 |
| Support Level | $15.55 | $20.00 |
| Resistance Level | $15.89 | $21.22 |
| Average True Range (ATR) | 0.19 | 0.93 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 46.30 | 85.90 |
Price Performance
Historical ComparisonAbout ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.